Ozmosi | NIO-752 Drug Profile

Product Description

NIO-752 is a drug candidate from Novartis Pharmaceutical for use in patients with progressive supranuclear palsy (PSP). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04539041)

Mechanisms of Action: Tau Antagonist

Novel Mechanism: Yes

Modality: Antibody Drug Conjugate

Route of Administration: Injection

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: Europe
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for NIO-752

Countries in Clinic: Canada, Finland, France, Germany, Spain, Sweden, United Kingdom, United States

Active Clinical Trial Count: 3

Recent & Upcoming Milestones

Highest Development Phases

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT05469360	CNIO752B12201	P1	Recruiting	Alzheimer Disease\|Tauopathies\|Memory Disorders\|Brain Diseases\|Cognitive Dysfunction	2026-09-11	50%	2025-08-29	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT06372821	NIO-SILK	P1	Recruiting	Alzheimer Disease\|Arthrogryposis	2026-07-01		2025-07-31	Primary Completion Date\|Primary Endpoints\|Start Date\|Study Completion Date\|Treatments\|Trial Status
NCT04539041	CNIO752A02101	P1	Completed	Paralysis\|Supranuclear Palsy, Progressive\|Progressive Supranuclear Palsy	2024-10-17	4%	2024-11-21	Primary Endpoints\|Treatments\|Trial Status

Recent News Events

Date	Type	Title
02/16/2024	PubMed	Prognostic and Predictive Factors in Early Alzheimer's Disease: A Systematic Review.
02/01/2024	PubMed	Posterior cortical atrophy: new insights into treatments and biomarkers for Alzheimer's disease.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

NIO-752

Alternative Names: NIO-752, NIO 752, NIO752 Clinical Status: Active Latest Update: 2025-08-28 Latest Update Note: Clinical Trial Update